Telemus Capital LLC Has $321,000 Holdings in Bristol-Myers Squibb Co (BMY)
Telemus Capital LLC lowered its position in Bristol-Myers Squibb Co (NYSE:BMY) by 43.7% in the 3rd quarter, Holdings Channel reports. The firm owned 5,041 shares of the biopharmaceutical company’s stock after selling 3,909 shares during the quarter. Telemus Capital LLC owned 3.08% of Bristol-Myers Squibb worth $321,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of BMY. Renaissance Technologies LLC increased its position in shares of Bristol-Myers Squibb by 108.5% during the second quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock worth $751,563,000 after acquiring an additional 7,020,200 shares during the period. Franklin Resources Inc. increased its position in shares of Bristol-Myers Squibb by 185.2% during the second quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock worth $339,830,000 after acquiring an additional 3,960,191 shares during the period. Janus Henderson Group PLC increased its position in shares of Bristol-Myers Squibb by 2,990.5% during the second quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock worth $202,494,000 after acquiring an additional 3,516,536 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of Bristol-Myers Squibb by 42,071.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock worth $185,634,000 after acquiring an additional 3,323,649 shares during the period. Finally, Parnassus Investments CA purchased a new position in shares of Bristol-Myers Squibb during the third quarter worth approximately $172,098,000. 69.67% of the stock is currently owned by institutional investors and hedge funds.
Bristol-Myers Squibb Co (BMY) opened at $61.85 on Wednesday. The stock has a market cap of $101,230.00, a P/E ratio of 24.35, a P/E/G ratio of 2.22 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Co has a 1-year low of $46.01 and a 1-year high of $66.10.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.59%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.99%.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the transaction, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Theodore R. Samuels II purchased 4,000 shares of the business’s stock in a transaction on Friday, December 15th. The stock was purchased at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the acquisition, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.
A number of equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday. Jefferies Group reaffirmed a “buy” rating and set a $72.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Cowen reaffirmed a “hold” rating and set a $65.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, September 19th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Finally, Hilliard Lyons lowered shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 target price on the stock. in a research report on Tuesday, September 12th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $65.05.
TRADEMARK VIOLATION NOTICE: “Telemus Capital LLC Has $321,000 Holdings in Bristol-Myers Squibb Co (BMY)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/telemus-capital-llc-has-321000-holdings-in-bristol-myers-squibb-co-bmy/1800751.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.